Eli Lilly invites you to an insightful session on implementing disease-modifying therapies (DMTs) for Alzheimer's disease (AD) in clinical practice, with a focus on amyloid-targeting therapies (ATTs) for patients with early symptomatic AD. Featuring expert insights from Dr. Stephen Salloway, Professor of Neurology and Professor of Psychiatry and Human Behavior, and Dr.
Paul Yates, Consultant Geriatrician, the session will cover the role of anti-amyloid antibodies in AD management and practical considerations for their use in clinical practice. The session will also provide an opportunity to engage with the experts and explore key clinical considerations through an interactive Q&A. Date : November 21, 2026 Time : 7:00 PM to 8:00 PM IST Join this scientific session to gain practical insights into implementing disease-modifying therapies and navigating the clinical considerations involved…